A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC)
Phase II Study of Weekly Oral Methotrexate and Zidovudine (AZT) in Advanced Adenocarcinoma of the Pancreas and Hepatocellular Carcinoma
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study
Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial
Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study
Dose Volume Analysis of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Concurrent Cisplatinum and Etoposide with or without Consolidation Docetaxel
Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study
Pemetrexed plus Cetuximab in patients with Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Study
Cisplatin plus Etoposide plus Concurrent Chest Radiation with or without Consolidation Docetaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Study
Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) in Metastatic Breast Cancer: A Phase II Trial
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer
Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC)
A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin, combined with Celecoxib and Glutamine as first line therapy for advanced colorectal cancer
A Prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil plus Levamisole in the Treatment of Metastatic Colorectal Cancer
A Prospective Randomized Trial of Fluorouracil Versus Fluorouracil plus Cisplatin in the Treatment of Metastatic Colorectal Cancer
A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GEJ junction carcinomas
Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis
Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis
Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma
Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Study
BRE12-158: A Post-neoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients with Residual Triple-Negative Breast Cancer
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
